Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Peripheral / undifferentiated SpA Patients Chapter 15 When the picture changes

Remission, Treatment Reduction and Long-Term Outlook

What remission means, how treatment reduction differs from withdrawal, and what early peripheral SpA studies can and cannot predict.

Open accessEvidence reviewed:
All chapters in this collection

Understanding the diagnosis

  1. 1. Peripheral SpA, Undifferentiated SpA and a Working Diagnosis
  2. 2. Joints, Entheses and Dactylitis: Understanding the Peripheral Pattern
  3. 3. How the Diagnosis Is Built
  4. 4. New Symptoms: What Changes the Picture and When Not to Wait

Tests and imaging

  1. 5. Blood Tests and HLA-B27: What They Can and Cannot Tell You
  2. 6. Ultrasound, MRI, X-ray and Joint Aspiration: Choosing the Right Test

Treatment decisions

  1. 7. What Are We Actually Trying to Improve?
  2. 8. NSAIDs, Local Treatment and Conventional DMARDs
  3. 9. When Targeted Therapy Enters the Discussion

Daily life and follow-up

  1. 10. Movement, Feet, Hands, Work and Everyday Load
  2. 11. How Do We Know Treatment Is Working?
  3. 12. Pregnancy, Infection, Surgery and Other Medical Conditions

When the picture changes

  1. 13. Why the Diagnosis May Change
  2. 14. When Pain, Examination, Blood Tests and Imaging Disagree
  3. 15. Remission, Treatment Reduction and Long-Term Outlook

Research and future care

  1. 16. How New Research May Change Treatment

Feeling well can bring a new uncertainty: “Do I still need treatment?” That is a reasonable question, especially when medication has costs, monitoring requirements or adverse effects. The answer depends on what remission means in your case, how sustained it has been and what is known about reducing the particular treatment.

Remission is a state, not a guarantee

Clinical remission usually means that the findings used to define active disease are absent or very low. Definitions differ between studies and between disease patterns. A definition focused on joints, entheses and dactylitis does not automatically establish that skin, bowel or eye disease is also controlled.

Ask which manifestations are in remission and how that conclusion was reached. Normal blood tests alone may be insufficient if they did not reflect your disease when it was active. Conversely, some persistent pain may have a non-inflammatory explanation even when inflammatory disease is well controlled.

Sustained control matters

One good visit provides less information than consistent control over time. The review should consider flares, examination findings, function, treatment tolerance and associated disease. It should also ask whether other medicines, such as glucocorticoids, are temporarily masking activity.

The ABILITY-2 extension followed nonpsoriatic peripheral SpA during longer-term adalimumab treatment. Early response was associated with later remission, but the study does not provide a precise personal forecast. An open-label extension also answers a different question from a randomized treatment-withdrawal trial.

Reduction and withdrawal are different decisions

Tapering means a planned reduction in treatment exposure, which may involve dose or interval changes when appropriate for that medicine. Withdrawal means stopping it. Replacing a biologic with a conventional medicine is another distinct strategy.

These approaches should not be treated as equivalent. A small peripheral SpA study of replacing golimumab with methotrexate after remission found that many participants required golimumab again. That does not prove every reduction attempt will fail; it shows why the exact strategy and population matter.

What the CRESPA experience adds

CRESPA studied a selected group with very early peripheral disease. Follow-up after remission induction showed that some participants maintained remission after treatment withdrawal, while others relapsed. This is a reason to study who may benefit from early treatment and who can later remain well without it.

Plan the response to a flare before reducing treatment

If reduction is appropriate, agree on what will change, what symptoms or findings count as possible relapse, when review will occur and how to obtain earlier assessment. Record the starting state so later changes can be compared meaningfully.

New swelling, return of function-limiting stiffness or renewed associated-organ symptoms should be reported according to the plan. A new hot swollen joint still needs urgent evaluation for other causes. Do not assume every symptom after a dose change is a flare or restart leftover medication without agreed instructions.

Long-term outlook includes more than the label

Function, work participation, coexisting conditions, access to treatment and the burden of symptoms all matter. Some people retain a predominantly peripheral pattern; others develop a more specific disease association. Neither the word undifferentiated nor a single HLA-B27 result determines the course.

Continue to address rehabilitation, cardiovascular health and other routine medical needs alongside inflammation. A medication decision is only one part of long-term care. If symptoms persist in apparent remission, revisit their cause using the framework for conflicting findings.

The aim is the least burdensome effective plan supported by your current circumstances, with room to adapt. The research chapter explains why promising early-intervention results should inform a thoughtful discussion without becoming a promise that every patient can eventually stop treatment.

Sources and further reading

  1. CRESPA: Drug-free remission after induction therapy, 2018
  2. Peripheral SpA: Golimumab withdrawal with methotrexate step-down, 2021
  3. ABILITY-2: Three-year outcomes and predictors of remission
  4. CRESPA 10-year follow-up: Drug-free remission in early peripheral SpA including PsA, published 21 September 2026

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Peripheral SpASpondyloarthritis